PDF(Pubmed)
Abstract：
Direct oral anticoagulants (DOACs) have become the preferred option for treatment of venous thromboembolism due to their favorable profile compared with other agents such as vitamin K antagonists or low-molecular-weight heparin. However, findings from randomized controlled trials suggest efficacy and/or safety concerns with DOAC use in some clinical contexts. This illustrated review will summarize indications where DOACs have proven efficacy and safety, situations where they fall short, and situations where uncertainty remains compared with other treatments for venous thromboembolism.
摘要：
直接口服抗凝剂（DOAC）与其他药物（如维生素K拮抗剂或低分子量肝素）相比，具有良好的优势，已成为治疗静脉血栓栓塞的首选选择。然而,随机对照试验的结果表明,在某些临床情况下,DOAC的使用存在疗效和/或安全性问题.本综述将总结DOAC已证明疗效和安全性的适应症，他们做不到的情况，与其他静脉血栓栓塞治疗相比，不确定性仍然存在的情况。
